Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in The Netherlands. Issue 4 (5th February 2015)

• Record Type: Journal Article
• Authors: Ripping, T.M.; Verbeek, A.L.M.; Fracheboud, J.; de Koning, H.J.; van Ravesteyn, N.T.; Broeders, M.J.M.
• Is Part Of: International journal of cancer. Volume 137:Issue 4(2015:Aug. 15)
• Page Start: 921
• Page End: 929
• Publication Date: 2015-02-05
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29452
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>A drawback of early detection of breast cancer through mammographic screening is the diagnosis of breast cancers that would never have become clinically detected. This phenomenon, called overdiagnosis, is ideally quantified from the breast cancer incidence of screened and unscreened cohorts of women with follow‐up until death. Such cohorts do not exist, requiring other methods to estimate overdiagnosis. We are the first to quantify overdiagnosis from invasive breast cancer and ductal carcinoma in situ (DCIS) in birth cohorts using an age‐period‐cohort ‐model (APC‐model) including variables for the initial and subsequent screening rounds and a 5‐year period after leaving screening. Data on the female population and breast cancer incidence were obtained from Statistics Netherlands, "Stichting Medische registratie" and the Dutch Cancer Registry for women aged 0–99 years. Data on screening participation was obtained from the five regional screening organizations. Overdiagnosis was calculated from the excess breast cancer incidence in the screened group divided by the breast cancer incidence in presence of screening for women aged 20–99 years (population perspective) and for women in the screened‐age range (individual perspective). Overdiagnosis of invasive breast cancer was 11% from the population perspective and 17% from the invited women perspective in birth cohorts screened from age 49 to 74. For invasive breast cancer and DCIS together, overdiagnosis was 14% from population perspective and 22% from invited women perspective. A major strength of an APC‐model including the different phases of screening is that it allows to estimate overdiagnosis in birth cohorts, thereby preventing overestimation.</p> </abstract>